{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:21:27Z","timestamp":1792466487728,"version":"4.5.0"},"reference-count":105,"publisher":"Tech Science Press","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2025.063719","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:20:02Z","timestamp":1752139202000},"page":"2309-2329","source":"Crossref","is-referenced-by-count":12,"title":["Advances in Tumor Microenvironment and Immunotherapeutic Strategies for Hepatocellular Carcinoma"],"prefix":"10.32604","volume":"33","author":[{"given":"Jiahao","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liucui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"ref2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jhep.2024.06.018","article-title":"Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection","volume":"81","author":"Fuster-Anglada","year":"2024","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1158\/1055-9965.EPI-11-0643","article-title":"International trends in liver cancer incidence rates","volume":"20","author":"Center","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/liv.15251","article-title":"Changing epidemiology of hepatocellular carcinoma in Asia","volume":"42","author":"Zhang","year":"2022","journal-title":"Liver Int"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1136\/gutjnl-2020-320716","article-title":"Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma","volume":"70","author":"Shang","year":"2021","journal-title":"Gut"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/toxsci\/kfae126","article-title":"MAD2L1 supports MYC-driven liver carcinogenesis in mice and predicts poor prognosis in human hepatocarcinoma","volume":"203","author":"Lu","year":"2025","journal-title":"Toxicol Sci"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jhep.2024.12.016","article-title":"Single-cell RNA seq-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma","volume":"82","author":"Cappuyns","year":"2025","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3892\/ol.2021.12540","article-title":"Clinical outcomes and influencing factors of PD-1\/PD-L1 in hepatocellular carcinoma","volume":"21","author":"Wang","year":"2021","journal-title":"Oncol Lett"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.31310","article-title":"Role of the mammalian target of rapamycin pathway in liver cancer: from molecular genetics to targeted therapies","volume":"73","author":"Lu","year":"2021","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e163291","DOI":"10.1172\/JCI163291","article-title":"Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models","volume":"133","author":"Lu","year":"2023","journal-title":"J Clin Invest"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.32604\/or.2023.028964","article-title":"Construction of the panoptosis-related gene model and characterization of tumor microenvironment infiltration in hepatocellular carcinoma","volume":"31","author":"Shi","year":"2023","journal-title":"Oncol Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e13576","DOI":"10.1111\/cpr.13576","article-title":"Integrated single-cell transcriptomics reveals the hypoxia-induced inflammation-cancer transformation in NASH-derived hepatocellular carcinoma","volume":"57","author":"Liang","year":"2024","journal-title":"Cell Prolif"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"101041","DOI":"10.1016\/j.drup.2023.101041","article-title":"The promising role of tumor-associated macrophages in the treatment of cancer","volume":"73","author":"Wang","year":"2024","journal-title":"Drug Resist Updat"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/bjc.2017.356","article-title":"TAMeless traitors: macrophages in cancer progression and metastasis","volume":"117","author":"Aras","year":"2017","journal-title":"Br J Cancer"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"13455","DOI":"10.1038\/s41598-019-49878-4","article-title":"Tumor infiltrating lymphocytes and macrophages improve survival in microsatellite unstable colorectal cancer","volume":"9","author":"Narayanan","year":"2019","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/cancers14010226","article-title":"Tumor-associated macrophages in hepatocellular carcinoma pathogenesis, prognosis and therapy","volume":"14","author":"Arvanitakis","year":"2022","journal-title":"Cancers"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2014.10.029","article-title":"Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma","volume":"62","author":"Yeung","year":"2015","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e8458","DOI":"10.7717\/peerj.8458","volume":"8","author":"Sun","year":"2020","journal-title":"PeerJ"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41698-018-0048-z","article-title":"Role of nonresolving inflammation in hepatocellular carcinoma development and progression","volume":"2","author":"Yu","year":"2018","journal-title":"npj Precis Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1002\/cam4.2327","article-title":"Crosstalk between cancer and immune cells: role of tumor-associated macrophages in the tumor microenvironment","volume":"8","author":"Wang","year":"2019","journal-title":"Cancer Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/hep.27867","article-title":"Myeloid cells in hepatocellular carcinoma","volume":"62","author":"Wan","year":"2015","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","article-title":"Myeloid-derived suppressor cells coming of age","volume":"19","author":"Veglia","year":"2018","journal-title":"Nat Immunol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12943-019-1047-6","article-title":"Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities","volume":"18","author":"Lu","year":"2019","journal-title":"Mol Cancer"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/onc.2016.273","article-title":"Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells","volume":"36","author":"Deng","year":"2017","journal-title":"Oncogene"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1136\/gutjnl-2017-314032","article-title":"Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy","volume":"67","author":"Zhou","year":"2018","journal-title":"Gut"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e1564505","DOI":"10.1080\/2162402X.2018.1564505","article-title":"Tim-3\/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients","volume":"8","author":"Limagne","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e13588","DOI":"10.1111\/cpr.13588","article-title":"Requirements for human natural killer cells","volume":"57","author":"Niu","year":"2024","journal-title":"Cell Prolif"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.omto.2018.10.001","article-title":"Myelolytic treatments enhance oncolytic herpes virotherapy in models of ewing sarcoma by modulating the immune microenvironment","volume":"11","author":"Denton","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3390\/cancers15030906","article-title":"SAINT: a phase I\/expanded phase II study using safe amounts of ipilimumab, nivolumab and trabectedin as first-line treatment of advanced soft tissue sarcoma","volume":"15","author":"Gordon","year":"2023","journal-title":"Cancers"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.2174\/1381612828666220526125806","article-title":"Trabectedin in cancers: mechanisms and clinical applications","volume":"28","author":"Wang","year":"2022","journal-title":"Curr Pharm Des"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3390\/molecules29020331","article-title":"Trabectedin and lurbinectedin modulate the interplay between cells in the tumour microenvironment-progresses in their use in combined cancer therapy","volume":"29","author":"Povo-Retana","year":"2024","journal-title":"Molecules"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1158\/0008-5472.CAN-23-3966","article-title":"Estrogen induces LCAT to maintain cholesterol homeostasis and suppress hepatocellular carcinoma development","volume":"84","author":"He","year":"2024","journal-title":"Cancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.cgh.2017.05.036","article-title":"Estrogen replacement reduces risk and increases survival times of women with hepatocellular carcinoma","volume":"15","author":"Hassan","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3748\/wjg.v24.i1.1","article-title":"Estrogen, estrogen receptors, and hepatocellular carcinoma: are we there yet?","volume":"24","author":"Sukocheva","year":"2018","journal-title":"World J Gastroenterol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1210\/endrev\/bnac017","article-title":"Estrogen receptor signaling in the immune system","volume":"44","author":"Chakraborty","year":"2023","journal-title":"Endocr Rev"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.intimp.2019.02.019","article-title":"\u03b3\u03b4 T cells in hepatocellular carcinoma patients present cytotoxic activity but are reduced in potency due to IL-2 and IL-21 pathways","volume":"70","author":"Jiang","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/jcp.25016","article-title":"Treg(s) in cancer: friends or foe?","volume":"230","author":"Wolf","year":"2015","journal-title":"J Cell Physiol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3390\/vaccines9101184","article-title":"The immunology of hepatocellular carcinoma","volume":"9","author":"Lawal","year":"2021","journal-title":"Vaccines"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"7971","DOI":"10.3748\/wjg.v20.i24.7971","article-title":"Roles of tregs in development of hepatocellular carcinoma: a meta-analysis","volume":"20","author":"Zhao","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.bbadis.2013.01.005","article-title":"Dendritic cells and liver fibrosis","volume":"1832","author":"Rahman","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nature16962","article-title":"Expanding antigen-specific regulatory networks to treat autoimmunity","volume":"530","author":"Clemente-Casares","year":"2016","journal-title":"Nature"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"7378","DOI":"10.3390\/ijms21197378","article-title":"Dendritic cell and T cell crosstalk in liver fibrogenesis and hepatocarcinogenesis: implications for prevention and therapy of liver cancer","volume":"21","author":"Lurje","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3390\/life11121355","article-title":"Immunotherapy for hepatocellular carcinoma: new prospects for the cancer therapy","volume":"11","author":"Fasano","year":"2021","journal-title":"Life"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.3389\/fimmu.2018.02795","article-title":"Macrophages in the aging liver and age-related liver disease","volume":"9","author":"Stahl","year":"2018","journal-title":"Front Immunol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke","year":"2017","journal-title":"J Hepatol"},{"key":"ref48","first-page":"e82171","article-title":"Deciphering the matrisome: extracellular matrix remodeling in liver cirrhosis and hepatocellular carcinoma","volume":"17","author":"Chaulagain","year":"2025","journal-title":"Cureus"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.3350\/cmh.2023.0244","article-title":"The role of the hepatic autonomic nervous system","volume":"29","author":"Luo","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","article-title":"Liver sinusoidal endothelial cells: physiology and role in liver diseases","volume":"66","author":"Poisson","year":"2017","journal-title":"J Hepatol"},{"key":"ref51","first-page":"1845","article-title":"The role of liver sinusoidal endothelial cells in cancer liver metastasis","volume":"11","author":"Yang","year":"2021","journal-title":"Am J Cancer Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/liv.12262","article-title":"Endothelial transdifferentiation in hepatocellular carcinoma: loss of Stabilin-2 expression in peri-tumourous liver correlates with increased survival","volume":"33","author":"G\u00e9raud","year":"2013","journal-title":"Liver Int"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"217243","DOI":"10.1016\/j.canlet.2024.217243","article-title":"Hepatic stellate cells promote hepatocellular carcinoma development by regulating histone lactylation: novel insights from single-cell RNA sequencing and spatial transcriptomics analyses","volume":"604","author":"Yu","year":"2024","journal-title":"Cancer Lett"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"e13500","DOI":"10.1111\/cpr.13500","volume":"56","author":"Chen","year":"2023","journal-title":"Cell Prolif"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"36750","DOI":"10.1038\/srep36750","article-title":"Activated hepatic stellate cells play pivotal roles in hepatocellular carcinoma cell chemoresistance and migration in multicellular tumor spheroids","volume":"6","author":"Song","year":"2016","journal-title":"Sci Rep"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/ijc.32899","article-title":"Therapeutic modulators of hepatic stellate cells for hepatocellular carcinoma","volume":"147","author":"Ruan","year":"2020","journal-title":"Int J Cancer"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3389\/fimmu.2020.00552","article-title":"Liver, tumor and viral hepatitis: key players in the complex balance between tolerance and immune activation","volume":"11","author":"S\u00e4llberg","year":"2020","journal-title":"Front Immunol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/hep.22346","article-title":"Multidrug resistance-associated proteins are crucial for the viability of activated rat hepatic stellate cells","volume":"48","author":"Hannivoort","year":"2008","journal-title":"Hepatology"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1083\/jcb.201211138","article-title":"Extracellular vesicles: exosomes, microvesicles, and friends","volume":"200","author":"Raposo","year":"2013","journal-title":"J Cell Biol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41586-022-05289-6","article-title":"Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis","volume":"610","author":"Filliol","year":"2022","journal-title":"Nature"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"e13592","DOI":"10.1111\/cpr.13592","article-title":"Single-cell RNA sequencing to explore cancer-associated fibroblasts heterogeneity: single vision for heterogeneous environment","volume":"57","author":"Zhang","year":"2024","journal-title":"Cell Prolif"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"217244","DOI":"10.1016\/j.canlet.2024.217244","article-title":"The role of Hippo\/YAP1 in cancer-associated fibroblasts: literature review and future perspectives","volume":"604","author":"Athavale","year":"2024","journal-title":"Cancer Lett"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3390\/ijms20071723","article-title":"The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma","volume":"20","author":"Baglieri","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.3390\/ijms22147575","article-title":"TGF-\u03b2 signaling: from tissue fibrosis to tumor microenvironment","volume":"22","author":"Chung","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","article-title":"Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer","volume":"6","author":"Wu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.7150\/ijbs.45446","article-title":"Cancer-associated fibroblasts induce epithelial-mesenchymal transition via the transglutaminase 2-dependent IL-6\/IL6R\/STAT3 axis in hepatocellular carcinoma","volume":"16","author":"Jia","year":"2020","journal-title":"Int J Biol Sci"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2014.08.039","article-title":"Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells","volume":"147","author":"Wan","year":"2014","journal-title":"Gastroenterology"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.3892\/or.2015.3783","article-title":"STAT3 cooperates with twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells","volume":"33","author":"Zhang","year":"2015","journal-title":"Oncol Rep"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00109-018-1731-9","volume":"97","author":"Li","year":"2019","journal-title":"J Mol Med"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41575-021-00508-3","article-title":"Cancer stem cells in hepatocellular carcinoma\u2014from origin to clinical implications","volume":"19","author":"Lee","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12929-017-0341-0","article-title":"Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets","volume":"24","author":"Tsai","year":"2017","journal-title":"J Biomed Sci"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","article-title":"Immune checkpoint inhibitors: basics and challenges","volume":"26","author":"Li","year":"2019","journal-title":"Curr Med Chem"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: advances and bottlenecks","volume":"14","author":"Rui","year":"2023","journal-title":"Front Immunol"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1001\/jama.2017.14155","article-title":"Targeting immune checkpoints in cancer therapy","volume":"318","author":"Topalian","year":"2017","journal-title":"JAMA"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.ccell.2024.08.007","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.32604\/or.2024.047524","article-title":"CircMYBL2 facilitates hepatocellular carcinoma progression by regulating E2F1 expression","volume":"32","author":"Yi","year":"2024","journal-title":"Oncol Res"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"1382520","DOI":"10.3389\/fimmu.2024.1382520","article-title":"Comprehensive pan-cancer analysis of YBX family reveals YBX2 as a potential biomarker in liver cancer","volume":"15","author":"Yuan","year":"2024","journal-title":"Front Immunol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"100907","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist Updat"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"1296341","DOI":"10.3389\/fimmu.2023.1296341","article-title":"PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment","volume":"14","author":"Parvez","year":"2023","journal-title":"Front Immunol"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1200\/JCO.2022.40.4_suppl.436","article-title":"Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: results from the phase 2 study 22 (NCT02519348)","volume":"40","author":"Lim","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/cancers12051089","article-title":"Scientific rationale for combined immunotherapy with PD-1\/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma","volume":"12","author":"Kudo","year":"2020","journal-title":"Cancers"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1002\/mco2.474","article-title":"Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy","volume":"5","author":"Luo","year":"2024","journal-title":"MedComm"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12943-024-02156-y","article-title":"Regulatory T cells in immune checkpoint blockade antitumor therapy","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"eadf2223","DOI":"10.1126\/sciimmunol.adf2223","article-title":"Beyond T cell exhaustion: TIM-3 regulation of myeloid cells","volume":"9","author":"Dixon","year":"2024","journal-title":"Sci Immunol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"107933","DOI":"10.1016\/j.intimp.2021.107933","article-title":"TIM-3: an update on immunotherapy","volume":"99","author":"Zhao","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"217412","DOI":"10.1016\/j.canlet.2024.217412","article-title":"TIM3 on natural killer cells regulates antibody-dependent cellular cytotoxicity in HER2-positive gastric cancer","volume":"611","author":"Tsutsumi","year":"2024","journal-title":"Cancer Lett"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1158\/1078-0432.CCR-24-2131","article-title":"Correction: phase I\/Ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors","volume":"30","author":"Curigliano","year":"2024","journal-title":"Clin Cancer Res"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.scib.2024.11.029","article-title":"Dual inhibition of PD-1 and LAG-3: uncovering mechanisms to reverse T cell exhaustion and enhance anti-tumor immunity","volume":"70","author":"Zhou","year":"2024","journal-title":"Sci Bull"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-23-2396","article-title":"Model-informed clinical pharmacology profile of a novel fixed-dose combination of nivolumab and relatlimab in adult and adolescent patients with solid tumors","volume":"30","author":"Zhao","year":"2024","journal-title":"Clin Cancer Res"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1186\/s12885-024-12876-5","article-title":"Relationship between TIGIT expression on T cells and the prognosis of patients with hepatocellular carcinoma","volume":"24","author":"Guo","year":"2024","journal-title":"BMC Cancer"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"101961","DOI":"10.1016\/j.tranon.2024.101961","article-title":"A novel epigenetic strategy to concurrently block immune checkpoints PD-1\/PD-L1 and CD155\/TIGIT in hepatocellular carcinoma","volume":"45","author":"Assal","year":"2024","journal-title":"Transl Oncol"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1159\/000535154","article-title":"A phase 1b study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma: extended analysis of study 116","volume":"13","author":"Kudo","year":"2024","journal-title":"Liver Cancer"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jhep.2020.11.037","article-title":"CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma","volume":"74","author":"Diggs","year":"2021","journal-title":"J Hepatol"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/LVT.0000000000000087","article-title":"Feasibility, safety, and outcome of second-line nivolumab\/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma","volume":"29","author":"Di Marco","year":"2023","journal-title":"Liver Transpl"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10637-022-01248-0","article-title":"Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience","volume":"40","author":"Wu","year":"2022","journal-title":"Invest New Drugs"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"102622","DOI":"10.1016\/j.eclinm.2024.102622","article-title":"Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody\/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study","volume":"72","author":"Jin","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40259-024-00691-0","article-title":"The evolving applications of bispecific antibodies: reaping the harvest of early sowing and planting new seeds","volume":"39","author":"Ellerman","year":"2024","journal-title":"BioDrugs"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/hep.22490","article-title":"The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor\/angiopoietin-driven sprouting neovascularization","volume":"48","author":"Zeng","year":"2008","journal-title":"Hepatology"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/2326-6066.CIR-23-1102","article-title":"Multifunctional bispecific nanovesicles targeting SLAMF7 trigger potent antitumor immunity","volume":"12","author":"Zhu","year":"2024","journal-title":"Cancer Immunol Res"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-9\/OncolRes-33-09-63719\/OncolRes-33-63719.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:11:37Z","timestamp":1763345497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n9\/63624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":105,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2025.063719","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}